株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性呼吸窮迫症候群(ARDS)- 市場洞察、疫学、市場予測

Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 401809
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
急性呼吸窮迫症候群(ARDS)- 市場洞察、疫学、市場予測 Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030
出版日: 2020年01月01日 ページ情報: 英文 150 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の急性呼吸窮迫症候群(ARDS)の2017年の市場規模は9億3,280万米ドルと推計されています。単独で病状を改善させる薬剤が存在しないため、急性呼吸窮迫症候群(ARDS)の治療には支持療法が行われています。今後、有望な治療薬の登場によって市場が拡大する可能性があります。

当レポートでは、主要7カ国の急性呼吸窮迫症候群(ARDS)市場を調査し、市場および疾患の概要、重症度・危険因子・国別の疫学的予測、現行治療、アンメットニーズ、適応外医薬品および開発中の新薬の概要、全体および各国の市場規模の推移と予測、市場の成長要因および障壁の分析などをまとめています。

目次

第1章 重要洞察

第2章 急性呼吸窮迫症候群(ARDS)の市場概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 急性呼吸窮迫症候群(ARDS):疾患背景と概要

  • イントロダクション
  • 原因とリスク要因
  • 病態生理
  • 病期
  • 人工呼吸器関連肺傷害(VILI)
  • 人工呼吸器関連肺傷害(VILI)の決定因子
  • 急性呼吸窮迫症候群(ARDS)の診断

第4章 疫学と患者人口

  • 主な調査結果
  • 調査手法

第5章 主要7カ国の疫学分析

  • 主要7カ国の急性呼吸窮迫症候群(ARDS)の総罹患数
  • 主要7カ国の急性呼吸窮迫症候群(ARDS)の罹患数:重症度別

第6章 米国の疫学

  • 仮定と根拠
  • 急性呼吸窮迫症候群(ARDS)の総罹患数
  • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
  • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別

第7章 欧州5カ国の疫学

  • ドイツの疫学
    • 仮定と根拠
    • 急性呼吸窮迫症候群(ARDS)の総罹患数
    • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
    • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別
  • フランスの疫学
    • 仮定と根拠
    • 急性呼吸窮迫症候群(ARDS)の総罹患数
    • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
    • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別
  • イタリアの疫学
    • 仮定と根拠
    • 急性呼吸窮迫症候群(ARDS)の総罹患数
    • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
    • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別
  • スペインの疫学
    • 仮定と根拠
    • 急性呼吸窮迫症候群(ARDS)の総罹患数
    • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
    • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別
  • 英国の疫学
    • 仮定と根拠
    • 急性呼吸窮迫症候群(ARDS)の総罹患数
    • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
    • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別

第8章 日本の疫学

  • 仮定と根拠
  • 急性呼吸窮迫症候群(ARDS)の総罹患数
  • 急性呼吸窮迫症候群(ARDS)の罹患数:重症度別
  • 急性呼吸窮迫症候群(ARDS)の罹患数:危険因子別

第9章 治療アルゴリズムと現行治療

  • 急性呼吸窮迫症候群(ARDS)の治療と支援

第10章 急性呼吸窮迫症候群(ARDS)のガイドライン案

  • 米国胸部医学会(ATS)、欧州集中治療医学会(ESICM)
  • 日本呼吸療法医学会(JRCM)、日本集中治療医学会(JSICM)

第11章 アンメットニーズ

第12章 急性呼吸窮迫症候群(ARDS)治療薬の適応外使用

  • 神経筋遮断薬(NMBA)
    • 製品説明
    • 作用機序
    • 長所と短所
    • 臨床開発
  • 吸入血管拡張薬
    • 吸入肺血管拡張薬
  • コルチコステロイド

第13章 新薬

  • キークロスコンペティション
  • Traumakine:Faron Pharmaceuticals
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 臨床試験の情報
    • 安全性と有効性
    • 製品プロファイル
  • Remodulin (Treprostinil Inhalation Solution):United Therapeutics
  • Bio-11006:BioMarck Pharmaceuticals
  • Ulinastatin:Techpool Bio-Pharma
  • MultiStem:Athersys
  • Solnatide (AP301):APEPTICO Forschung und Entwicklung GmbH

第14章 開発中止薬

  • APN01(GSK2586881):Apeiron Biologics / GlaxoSmithKline
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • GSK2862277:GlaxoSmithKline
  • IC14:Implicit Bioscience

第15章 急性呼吸窮迫症候群(ARDS):主要7ヶ国の市場分析

  • 主な調査結果
  • 市場予測の仮定
  • 主要7カ国の急性呼吸窮迫症候群(ARDS)の総市場規模
  • 主要7カ国の急性呼吸窮迫症候群(ARDS)の市場規模:治療薬別

第16章 米国市場の見通し

第17章 米国の市場規模

  • 急性呼吸窮迫症候群(ARDS)の総市場規模
  • 急性呼吸窮迫症候群(ARDS)の市場規模:治療薬別

第18章 欧州5カ国市場の見通し

  • ドイツの市場規模
    • 急性呼吸窮迫症候群(ARDS)の総市場規模
    • 急性呼吸窮迫症候群(ARDS)の市場規模:治療薬別
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模

第19章 日本市場の見通し

  • 日本の市場規模
    • 急性呼吸窮迫症候群(ARDS)の総市場規模
    • 急性呼吸窮迫症候群(ARDS)の市場規模:治療薬別

第20章 市場の成長要因

第21章 市場の障壁

第22章 付録

  • 調査手法

第23章 DelveInsightのサービス内容

第24章 免責事項

第25章 DelveInsightについて

図表

List of Tables

  • Table 1 : 7MM Acute Respiratory Distress Syndrome (ARDS) Epidemiology (2017-2030)
  • Table 2 : 7MM Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Germany (2017-2030)
  • Table 6 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in France (2017-2030)
  • Table 8 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Italy (2017-2030)
  • Table 10 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Spain (2017-2030)
  • Table 12 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in the UK (2017-2030)
  • Table 14 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Japan (2017-2030)
  • Table 16 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Acute Respiratory Distress Syndrome (ARDS) Epidemiology (2017-2030)
  • Figure 2 : 7MM Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in the United States (2017-2030)
  • Figure 4 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Germany (2017-2030)
  • Figure 6 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in France (2017-2030)
  • Figure 8 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Italy (2017-2030)
  • Figure 10 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Spain (2017-2030)
  • Figure 12 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in the UK (2017-2030)
  • Figure 14 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Acute Respiratory Distress Syndrome (ARDS) Epidemiology in Japan (2017-2030)
  • Figure 16 : Acute Respiratory Distress Syndrome (ARDS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
目次
Product Code: DIMI0011

DelveInsight's "Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, Acute Respiratory Distress Syndrome (ARDS) market share of the individual therapies, current and forecasted Acute Respiratory Distress Syndrome (ARDS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acute Respiratory Distress Syndrome (ARDS) Disease Understanding and Treatment Algorithm

The DelveInsight Acute Respiratory Distress Syndrome (ARDS) market report gives a thorough understanding of the Acute Respiratory Distress Syndrome (ARDS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Acute Respiratory Distress Syndrome (ARDS).

Treatment

It covers the details of conventional and current medical therapies available in the Acute Respiratory Distress Syndrome (ARDS) market for the treatment of the condition. It also provides Acute Respiratory Distress Syndrome (ARDS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Acute Respiratory Distress Syndrome (ARDS) Epidemiology

The Acute Respiratory Distress Syndrome (ARDS) epidemiology division provide insights about historical and current Acute Respiratory Distress Syndrome (ARDS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute Respiratory Distress Syndrome (ARDS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Acute Respiratory Distress Syndrome (ARDS) Epidemiology

The epidemiology segment also provides the Acute Respiratory Distress Syndrome (ARDS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Acute Respiratory Distress Syndrome (ARDS) Drug Chapters

Drug chapter segment of the Acute Respiratory Distress Syndrome (ARDS) report encloses the detailed analysis of Acute Respiratory Distress Syndrome (ARDS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acute Respiratory Distress Syndrome (ARDS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Acute Respiratory Distress Syndrome (ARDS) treatment.

Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Acute Respiratory Distress Syndrome (ARDS) treatment.

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

The Acute Respiratory Distress Syndrome (ARDS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acute Respiratory Distress Syndrome (ARDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Acute Respiratory Distress Syndrome (ARDS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acute Respiratory Distress Syndrome (ARDS) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Acute Respiratory Distress Syndrome (ARDS) market in 7MM.

The United States Market Outlook

This section provides the total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Japan is also mentioned.

Acute Respiratory Distress Syndrome (ARDS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome (ARDS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Respiratory Distress Syndrome (ARDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Respiratory Distress Syndrome (ARDS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Respiratory Distress Syndrome (ARDS) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acute Respiratory Distress Syndrome (ARDS) emerging therapies.

Reimbursement Scenario in Acute Respiratory Distress Syndrome (ARDS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Acute Respiratory Distress Syndrome (ARDS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acute Respiratory Distress Syndrome (ARDS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Acute Respiratory Distress Syndrome (ARDS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome (ARDS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome (ARDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acute Respiratory Distress Syndrome (ARDS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) market

Report Highlights

  • In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acute Respiratory Distress Syndrome (ARDS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute Respiratory Distress Syndrome (ARDS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis
  • Acute Respiratory Distress Syndrome (ARDS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Respiratory Distress Syndrome (ARDS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Acute Respiratory Distress Syndrome (ARDS) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute Respiratory Distress Syndrome (ARDS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acute Respiratory Distress Syndrome (ARDS) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acute Respiratory Distress Syndrome (ARDS) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Acute Respiratory Distress Syndrome (ARDS) market size during the forecast period (2017-2030)?
  • At what CAGR, the Acute Respiratory Distress Syndrome (ARDS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Acute Respiratory Distress Syndrome (ARDS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Acute Respiratory Distress Syndrome (ARDS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Acute Respiratory Distress Syndrome (ARDS)?
  • What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Respiratory Distress Syndrome (ARDS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Acute Respiratory Distress Syndrome (ARDS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Acute Respiratory Distress Syndrome (ARDS) in the USA, Europe, and Japan?
  • What are the Acute Respiratory Distress Syndrome (ARDS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
  • How many therapies are developed by each company for Acute Respiratory Distress Syndrome (ARDS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Acute Respiratory Distress Syndrome (ARDS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acute Respiratory Distress Syndrome (ARDS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Respiratory Distress Syndrome (ARDS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute Respiratory Distress Syndrome (ARDS)?
  • What are the global historical and forecasted market of Acute Respiratory Distress Syndrome (ARDS)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS) market
  • To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) market
  • To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market

Table of Contents

1. Key Insights

2. Executive Summary of Acute Respiratory Distress Syndrome (ARDS)

3. Competitive Intelligence Analysis for Acute Respiratory Distress Syndrome (ARDS)

4. Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance

  • 4.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Share (%) Distribution in 2017
  • 4.2. Acute Respiratory Distress Syndrome (ARDS) Total Market Share (%) Distribution in 2030

5. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Acute Respiratory Distress Syndrome (ARDS) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Acute Respiratory Distress Syndrome (ARDS) Treatment and Management
  • 8.2. Acute Respiratory Distress Syndrome (ARDS) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Acute Respiratory Distress Syndrome (ARDS) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Acute Respiratory Distress Syndrome (ARDS): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Acute Respiratory Distress Syndrome (ARDS) Market Size in 7MM
  • 13.3. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in the United States
    • 15.1.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Germany
    • 15.3.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in France
    • 15.4.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Italy
    • 15.5.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Spain
    • 15.6.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in the United Kingdom
    • 15.7.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Japan
    • 15.8.3. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute Respiratory Distress Syndrome (ARDS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight